Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration. Am J Clin Pathol 2017 Nov 20;148(6):485-493



Pubmed ID




Scopus ID

2-s2.0-85038129680 (requires institutional sign-in at Scopus site)   9 Citations


OBJECTIVES: CD30 is a protein thought to promote cell proliferation/survival and downregulate the immune response. Twenty percent to 40% of de novo diffuse large B-cell lymphomas (DLBCLs) express CD30, and some patients have been treated with the anti-CD30 agent brentuximab. In the solid organ transplant setting, allograft regulatory T cells (Tregs) have been shown to be modulated via CD30 signaling.

METHODS: Posttransplant lymphoproliferative disorders (PTLDs) constitute a heterogeneous group of lymphomas, and since CD30 expression has been rarely formally assessed in PTLDs, we analyzed a cohort of PTLDs.

RESULTS: We found that 26 (79%) of 33 PTLDs were CD30+. Of these, 17 (77%) of 22 DLBCL monomorphic PTLDs were CD30+ compared with 56 (38%) of 148 de novo DLBCLs (P = .009). The median FoxP3+ Treg count was higher in CD30+ than in CD30- PTLDs, 3.0 vs 0 (P = .012).

CONCLUSIONS: These findings suggest a pathophysiologic link between CD30 activity and Tregs and may indicate differential expression of CD30 in B-cell lymphomas arising in the setting of immune dysregulation.

Author List

Hartley C, Vaughan JW, Jarzembowski J, Kroft SH, Hosking P, Harrington AM, Olteanu H


Alexandra M. Harrington MD Professor in the Pathology department at Medical College of Wisconsin
Jason A. Jarzembowski MD, PhD Sr Associate Dean, CEO CSG, Professor in the Pathology department at Medical College of Wisconsin
Steven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Epstein-Barr Virus Infections
Ki-1 Antigen
Lymphoma, Large B-Cell, Diffuse
Lymphoproliferative Disorders
Middle Aged
Neoplasms, Second Primary
T-Lymphocytes, Regulatory
Young Adult